<DOC>
	<DOCNO>NCT00659048</DOCNO>
	<brief_summary>The primary objective study demonstrate clinically relevant additive inhibitory effect HPA-axis ciclesonide nasal spray concomitantly administer orally inhaled HFA-BDP . The secondary objective evaluate safety tolerability combine dose regimen orally inhale HFA-BDP ciclesonide nasal spray .</brief_summary>
	<brief_title>Investigation Potential Additive Inhibitory Effects HPA-Axis Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Beclomethasone Dipropionate ( HFA-BDP ) Patients With Perennial Allergic Rhinitis ( PAR ) ( BY9010/M1-408 )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<mesh_term>Ciclesonide</mesh_term>
	<criteria>1 . Male female , 18 60 year age . 2 . General good health , free concomitant condition treatment could interfere study conduct , influence interpretation study observations/results , put patient increase risk trial . 3 . A history PAR minimum one year immediately precede Screening Visit . 4 . A demonstrated sensitivity least one allergen know induce PAR standard prick intradermal test . A positive test define wheal diameter least 3 mm large control wheal prick test , 7 mm great control intradermal test . Documentation positive result within 12 month prior Screening Visit acceptable . 5 . Females childbearing potential currently take continue use medically reliable method contraception entire study duration ( e.g . oral , injectable , transcutaneous implantable contraceptive intrauterine device doublebarrier protection ) . Women childbearing potential , less 1 year postmenopausal , require negative plasma pregnancy test Screening Visit well last ontreatment visit . 6 . Capable understanding requirement , risk , benefit study participation , , judge investigator , capable give informed consent compliance study requirement ( visit , record keep , etc ) . 7 . Normal body weight evidence Body Mass Index ( BMI ) ³ 18 31 kg/m² , body weight &gt; 45 kg . 1 . Pregnancy , nursing , plan become pregnant donate gamete ( ova sperm ) vitro fertilization study period 30 day follow study period . 2 . History physical finding nasal pathology , include nasal polyp ( within last 60 day ) clinically significant respiratory tract malformation , recent nasal biopsy ( within last 60 day ) , nasal trauma , surgery atrophic rhinitis rhinitis medicamentosa ( within last 60 day ) . 3 . Participation investigational drug trial within 30 day precede Screening Visit ( S0 ) . 4 . A known hypersensitivity corticosteroid excipients formulation . 5 . History current evidence clinically relevant allergy idiosyncrasy drug food . 6 . History alcohol drug abuse within precede two year . 7 . History positive test HIV , hepatitis B hepatitis C. 8 . Use prohibit concomitant medication within prescribe ( per protocol ) withdrawal period prior Screening Visit ( S0 ) entire study duration . 9 . Previous participation intranasal ciclesonide study . 10 . Nonvaccinated exposure active infection , chickenpox measles within 21 day precede Screening Visit ( S0 ) . 11 . Exposure corticosteroid indication , chronic intermittent ( e.g . : asthma , contact dermatitis ) , past 2 month , presence underlying condition reasonably expect require treatment corticosteroid course study . 12 . Use topical corticosteroid concentration excess equivalent 1 % hydrocortisone dermatological condition past 1 month , presence underlying condition reasonably expect require treatment preparation course study . 13 . Clinically relevant abnormality clinical chemical , hematological laboratory variable . 14 . Chronic clinically relevant acute infection . 15 . Vegetarian diet unusual dietary habit would preclude subject 's acceptance standardize meal . 16 . Blood donation within last 30 day start study . 17 . Patients regular sleep pattern ( e.g . work night sleep daylight hour ) . 18 . Active asthma require treatment inhale systemic corticosteroid ; intermittent use beta agonist acceptable . 19 . History respiratory infection disorder [ include , limited bronchitis , pneumonia , common cold , acute chronic sinusitis , flu , severe acute respiratory syndrome ( SARS ) ] within 14 day precede Screening Visit ( S0 ) , development respiratory infection Runin Period . 20 . Use antibiotic therapy acute condition within 14 day prior Screening Visit ( S0 ) . Low dos antibiotic take prophylaxis permitted therapy start prior Screening Visit ( S0 ) AND expect continue throughout trial . 21 . Initiation immunotherapy study period dose escalation study period . However , initiation immunotherapy 90 day prior Screening Visit ( S0 ) AND use stable ( maintenance ) dose ( 30 day ) may consider inclusion . 22 . Failure adequately understand comply HFABDP instruction failure properly administer study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Perennial Allergic Rhinitis</keyword>
	<keyword>Ciclesonide</keyword>
	<keyword>PAR</keyword>
</DOC>